PREFACE前言2006年,赛诺菲旗下全球首款靶向CB1R的减肥药Rimonabant在欧洲上市,风靡一时。但是在后续的研究和使用过程中发现该药物进入大脑后会增加抑郁症和自杀的发生概率,因此在2007,该药物的上市申请被FDA拒绝,并于2009年在欧洲撤市。此后默沙东、辉瑞等药企也相继放弃了该靶点管线的研发。受限于安全性问题,靶向CB1R的药物的开发一度处于停滞状态,但得益于近两年减肥赛道的火爆...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.